- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ISR IMMUNE SYSTEM REGULATION Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 11,440 | +2,92 % | Intellia Therapeutics auf der Leerink-Konferenz: Gen-Editing-Therapie Lonbo-Z mit hohem Margenpotenzial | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,190 | +8,30 % | Barclays downgrades Pacific Biosciences stock rating on catalysts | ||
| ATAIBECKLEY | 3,320 | +0,61 % | AtaiBeckley Inc.: BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day | BPL-003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway reaffirmed through the planned early-2029 topline readouts... ► Artikel lesen | |
| BIOMERIEUX | 94,35 | +0,37 % | BIOMERIEUX: 2026 General Shareholders Meeting - Notice preparatory documents | ||
| BIO GREEN MED SOLUTION | 0,920 | 0,00 % | Bio Green Med Solution, Inc.: Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update | KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; "BGMS" or the "Company" (formerly Cyclacel Pharmaceuticals, Inc.)), a diversified... ► Artikel lesen | |
| GENUS | 31,200 | +0,65 % | Genus PLC - Notification of Major Holdings | ||
| ANAPTYSBIO | 55,50 | 0,00 % | AnaptysBio: Truist hebt Kursziel wegen Jemperli-Ausblick an | ||
| ABIONYX PHARMA | 3,285 | +0,61 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,560 | -6,67 % | Beyond Air Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd. | GARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| MEIRAGTX | 6,600 | -0,75 % | MeiraGTx Reports Third Quarter 2025 Financial and Operational Results | Entered into broad strategic collaboration with Eli Lilly and Company ("Lilly") in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company's AAV-AIPL1 program for treatment... ► Artikel lesen | |
| AKESO | 12,900 | +4,03 % | Akeso, Inc.: Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results | HONG KONG, March 4, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China... ► Artikel lesen | |
| MAAT PHARMA | 7,180 | +5,90 % | MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management | Oral presentation during Presidential Plenary Session to feature the final results of the ARES pivotal Phase 3 trial evaluating MaaT013 in acute Graft-versus-Host Disease (aGvHD) with gastrointestinal... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,047 | -3,50 % | Isofol Medical AB: Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise | GOTHENBURG, Sweden, 11 March 2026 - Isofol Medical AB ("Isofol" or the "Company") announces today that the Company has received a top guarantee commitment from existing shareholder Solasia Pharma K.K.... ► Artikel lesen | |
| DIAGONAL BIO | 0,004 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 19.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 19.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 19.12.2025ISIN NameCA74349R1055 PROPHECY... ► Artikel lesen | |
| QIAGEN | 35,760 | +1,06 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen bei unverändertem Kursziel von 54 US-Dollar von "Hold" auf "Buy" hochgestuft. Analyst Jan Koch kehrt nach seiner Abstufung im Januar... ► Artikel lesen |
Das Unternehmen ISR IMMUNE SYSTEM REGULATION HOLDING AB kann der Branche Biotechnologie zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISR IMMUNE SYSTEM REGULATION HOLDING AB finden Sie auf Wallstreet Online.